Continuous Glucose Monitoring Market size to exceed USD 47.1 Billion by 2034

Selbyville, DE. - The global continuous glucose monitoring market was estimated at USD 10.9 billion in 2024 and is estimated to grow from USD 12.4 billion in 2025 to USD 47.1 billion by 2034, at a CAGR of 16%, according to the latest report published by Global Market Insights Inc.  

The global surge in Type 1 and Type 2 diabetes cases is significantly boosting demand for CGM systems, as they provide real-time glucose tracking and help manage the disease more effectively than traditional fingerstick methods.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 10.9 billion
• 2025 Market Size: USD 12.4 billion
• 2034 Forecast Market Size: USD 47.1 billion
• CAGR (2025–2034): 16%  

Regional Insights:

• Largest Market: North America
• Fastest Growing Market: Asia Pacific
• Emerging Countries: India, Brazil, Mexico, South Africa  

Key Growth Drivers:

1. Shift toward personalized and preventive healthcare: Healthcare systems are increasingly focusing on prevention and long-term disease management.  
2. Advancements in sensor technology and miniaturization: Ongoing improvements in sensor accuracy, comfort, and wearability, such as smaller, longer-lasting, and more discreet devices, are increasing user adoption and reducing the burden of glucose monitoring.  
3. Integration with smart devices and digital health platforms: The ability of CGM systems to sync with smartphones, insulin pumps, and cloud-based platforms is transforming diabetes care.  
4. Supportive reimbursement policies and government initiatives: Many developed markets are expanding reimbursement coverage for CGM devices under public and private insurance schemes, making them more affordable and accessible for a broader patient base.  
5. Growing adoption among non-insulin-dependent and pre-diabetic patients: Beyond insulin-dependent diabetics, CGM is gaining popularity among individuals with pre-diabetes or those managing glucose levels through diet and lifestyle.  

Key Players:

• Abbott Laboratories led the market with over 56% share in 2024.  
• Some of the top players in this market include Dexcom, F. Hoffmann La-Roche, Medtronic, Ascensia Diabetes Care Holdings, Abbott Laboratories, which together held a 99% share in 2024.  

Key Challenges:

1. High cost of devices and maintenance: Despite technological advancements, CGM systems remain expensive, especially for uninsured or underinsured patients.  
2. Limited reimbursement in emerging markets: While reimbursement policies in developed countries are improving, many developing regions still lack insurance coverage for CGM systems.  
3. Accuracy and sensor reliability concerns: Although CGM accuracy has improved, discrepancies between interstitial fluid readings and blood glucose levels can still occur, particularly during rapid glucose changes.  
4. User compliance and device wearability: Some patients, especially children and the elderly, may find wearing CGM devices uncomfortable or intrusive.  
5. Data Privacy and Security Risks: As CGM devices increasingly connect to smartphones and cloud platforms, concerns around data privacy and cybersecurity are becoming more prominent.

Browse key industry insights spread across 130 pages with 139 market data tables and figures from the report, “Continuous Glucose Monitoring Market - By Component, By End Use - Global Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/continuous-glucose-monitoring-market  

Rising Adoption of Sensors

The sensors segment held a notable share in 2024. These components are critical for capturing real-time glucose readings in the interstitial fluid and transmitting accurate data to monitoring devices or mobile apps. As users demand longer wear times, greater comfort, and fewer calibrations, manufacturers are investing heavily in sensor innovation. The segment growth is also driven by technological improvements like extended sensor life, flexible wearables, and factory calibration. This growth reflects a strong shift toward convenience, especially for users managing diabetes outside of traditional clinical settings.  

Homecare Settings to Gain Traction

The home care settings segment will grow at a decent CAGR during 2025-2034. With patients increasingly prioritizing independence and remote care options, CGM systems are becoming essential tools for daily glucose monitoring at home. These devices allow users to manage their condition in real time, while sharing data with caregivers or physicians through digital platforms. This shift toward home-based diabetes management is not only reducing hospital visits but also empowering patients to take proactive control of their health.  

North America to Emerge as a Lucrative Region

North America continuous glucose monitoring market held a sustainable share in 2024, supported by a high diabetes prevalence, strong healthcare infrastructure, and favorable reimbursement policies. Major players are heavily investing in expanding access to CGM systems across both Type 1 and Type 2 diabetes patients, including those on non-insulin therapies. With regulatory agencies like the FDA streamlining approvals and the expansion of remote monitoring programs, North America continues to set the pace for innovation and adoption in this space.  

Major players in the continuous glucose monitoring market are Senseonics, Medtrum Technologies, i-SENS, F. Hoffmann-La Roche, Med Trust, Abbott Laboratories, Zhejiang POCTech, Sinocare, A. Menarini Diagnostics, Dexcom, and Medtronic.  

To solidify their position in the competitive CGM landscape, companies are focusing on technological advancement, strategic partnerships, and regulatory navigation. Leading firms are improving sensor accuracy, extending wear duration, and enabling seamless integration with insulin delivery systems and digital health apps. Collaborations with healthcare providers, insurers, and digital health startups are helping companies broaden access and enhance user engagement. Additionally, firms are investing in direct-to-consumer marketing and patient education to drive brand loyalty. Regulatory strategy also plays a crucial role, with companies working closely with agencies to secure approvals for over-the-counter use and expanded indications—ultimately positioning their products as standard tools for comprehensive diabetes care.